Ibrutinib + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
CoronaVirus Induced Disease-2019 (COVID-19)
Conditions
CoronaVirus Induced Disease-2019 (COVID-19)
Trial Timeline
Jun 6, 2020 → Jun 8, 2021
NCT ID
NCT04375397About Ibrutinib + Placebo
Ibrutinib + Placebo is a phase 2 stage product being developed by AbbVie for CoronaVirus Induced Disease-2019 (COVID-19). The current trial status is completed. This product is registered under clinical trial identifier NCT04375397. Target conditions include CoronaVirus Induced Disease-2019 (COVID-19).
What happened to similar drugs?
0 of 12 similar drugs in CoronaVirus Induced Disease-2019 (COVID-19) were approved
Approved (0) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04375397 | Phase 2 | Completed |
Competing Products
20 competing products in CoronaVirus Induced Disease-2019 (COVID-19)